A three part, randomised, double-blind, placebo-controlled single ascending dose study to assess safety, pharmacokinetics and pharmacodynamics of oral HTL0018318 in healthy younger adult and elderly subjects.
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs HTL 18318 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Heptares Therapeutics
- 05 Aug 2017 Status changed from recruiting to completed.
- 10 May 2016 New trial record